Barry Kappel
Founder at Sapience Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Scheinberg | M | 68 |
Sapience Therapeutics, Inc.
 Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | 7 years |
| Cary Sucoff | M | 71 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | 14 years |
| Howard H. Pien | M | 66 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | 8 years |
| Robert Ruffolo | M | 74 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | - |
| Christian Schade | M | 63 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | - |
| Andrew Sanford | M | - |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | 4 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Messinger | M | 49 | 11 years | |
| Isaac Blech | M | 73 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | 9 years |
| Robert Nowinski | M | - | 5 years | |
| Julia Gregory | F | 71 | 4 years | |
| Roger Pomerantz | M | 67 | 9 years | |
| Sol Barer | M | 76 | 12 years | |
| Nancy Dong | F | 58 | 10 years | |
| Bogdanos Natalie | F | 55 | 9 years | |
| Sheng Da Zan | M | 61 | - | |
| Michael Otto | M | 75 | 9 years | |
| David Low | M | 65 | 9 years | |
| Dimiter Tassev | M | - | - | |
| Samuel Broder | M | 79 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | - |
| Daniel Couto | M | 52 | 5 years | |
| Richard Sykes | M | 79 | - | |
| Michael Wittekind | M | 69 | 4 years | |
| David B. Huang | M | 49 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 23 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Barry Kappel
- Personal Network
